Larissa A. Korde

Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 5%percentile

0.406Author DataRank

Indexed papers

2in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Initial reporting from the prospective National Cancer Institute (NCI) COVID-19 in Cancer Patients Study (NCCAPS).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.6565

Top 45%

0.406DataRank

Top 45%5 citations

Ana F. Best, Sacha Gnjatic, Andrea Denicoff, Grace Mishkin, Melissa Bowman +15 more

Papers

Driven by 18 papers — median percentile 27. Top paper: “Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma”.

Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma

New England Journal of Medicine(2023)10.1056/nejmoa2211437

N/A

6.5DataRank · unranked

846 citations

Megan Othus, Yuanbin Chen, G. Paul Wright, Kathleen J. Yost, John Hyngstrom +48 more

Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer

New England Journal of Medicine(2023)10.1056/nejmoa2212856

N/A

4.5DataRank · unranked

216 citations

Samuel M. Niman, Monica Ruggeri, Fedro A. Peccatori, Hatem A. Azim, Marco Colleoni +34 more

A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART, SWOG S1609)

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-2182

N/A

3.8DataRank · unranked

125 citations

Megan Othus, Sandip Pravin Patel, Kathy D. Miller, Rashmi Chugh, Scott M. Schuetze +23 more

Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D)

European Journal of Cancer(2021)10.1016/j.ejca.2021.01.053

N/A

0.685DataRank · unranked

28 citations

Eileen Holmes, Christian Jackisch, Evandro de Azambuja, Frances Boyle, David W. Hillman +37 more

Initial reporting from the prospective National Cancer Institute (NCI) COVID-19 in Cancer Patients Study (NCCAPS).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.6565

Top 45%

0.406DataRank

Top 45%5 citations

Ana F. Best, Sacha Gnjatic, Andrea Denicoff, Grace Mishkin, Melissa Bowman +15 more

Hormonal factors predictive of fertility in patients with breast cancer interrupting adjuvant endocrine therapy to attempt pregnancy in POSITIVE trial

The Breast(2025)10.1016/j.breast.2025.104547

N/A

0.165DataRank · unranked

2 citations

Samuel M. Niman, Ann H. Partridge, Daniela Diego, Roswitha Kammler, Monica Ruggeri +31 more

A Randomized Phase IIb Study of Low-dose Tamoxifen in Chest-irradiated Cancer Survivors at Risk for Breast Cancer

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-3609

N/A

0DataRank · unranked

20 citations

Melanie R. Palomares, Lindsey Hageman, Yanjun Chen, Wendy Landier, Kandice Smith +17 more

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Annals of Oncology(2022)10.1016/j.annonc.2022.09.159

N/A

0DataRank · unranked

450 citations

Judy E. Garber, Richard D. Gelber, Greg Yothers, Manuel Taboada, L. Ross +93 more

Data from A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART, SWOG S1609)

(2023)10.1158/1078-0432.c.6530837

N/A

0DataRank · unranked

0 citations

Megan Othus, Sandip Pravin Patel, Kathy D. Miller, Rashmi Chugh, Scott M. Schuetze +23 more

Data from Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma

(2023)10.1158/2159-8290.c.6549583.v1

N/A

0DataRank · unranked

0 citations

Megan Othus, Sapna P. Patel, Ahmad A. Tarhini, Vernon K. Sondak, Michael V. Knopp +26 more

Fertility Preservation and Assisted Reproduction in Patients With Breast Cancer Interrupting Adjuvant Endocrine Therapy to Attempt Pregnancy

Journal of Clinical Oncology(2024)10.1200/jco.23.02292

N/A

0DataRank · unranked

27 citations

Samuel M. Niman, Ann H. Partridge, Isabelle Demeestere, Monica Ruggeri, Marco Colleoni +31 more

Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)]

ESMO Open(2024)10.1016/j.esmoop.2024.103938

N/A

0DataRank · unranked

9 citations

M. Piccart-Gebhart, Shona Fielding, John Townend, D.W. Hillman, M. Colleoni +37 more

Correction to: Tolerability and toxicity of trastuzumab or trastuzumab + lapatinib in older patients: a sub‑analysis of the ALTTO trial (BIG 2‑06; NCCTG (Alliance) N063D)

Breast Cancer Research and Treatment(2021)10.1007/s10549-021-06409-y

N/A

0DataRank · unranked

0 citations

Dominique Agbor‐Tarh, Lissandra Dal Lago, Larissa A. Korde, Florentine Hilbers, Christian Jackisch +9 more

Dual anti-CTLA-4 and anti-PD-1 blockade in metaplastic carcinoma of the breast: Dart (SWOG S1609, Cohort 36).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.1073

N/A

0DataRank · unranked

32 citations

Megan Othus, Sandip Pravin Patel, Young Kwang Chae, Kathy D. Miller, Rashmi Chugh +8 more

S1801: A randomized phase II trial of adjuvant versus neoadjuvant pembrolizumab (PEM) for melanoma.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.tps10090

N/A

0DataRank · unranked

1 citations

Megan Othus, James Moon, Michael T. Tetzlaff, Elizabeth I. Buchbinder, Vernon K. Sondak +8 more

Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma

Cancer Discovery(2021)10.1158/2159-8290.cd-21-1141

N/A

0DataRank · unranked

102 citations

Megan Othus, Sapna P. Patel, Ahmad A. Tarhini, Vernon K. Sondak, Michael V. Knopp +26 more

S1801: A randomized trial of adjuvant versus neoadjuvant pembrolizumab for melanoma.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.tps9585

N/A

0DataRank · unranked

3 citations

Megan Othus, James Moon, Michael T. Tetzlaff, Elizabeth I. Buchbinder, Vernon K. Sondak +9 more

Initial report on hospitalized cancer patients with COVID-19 from the National Cancer Institute (NCI) COVID-19 in Cancer Patients Study (NCCAPS).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.6566

Top 100%

0DataRank

Top 100%0 citations

Ana F. Best, Alok A. Khorana, Steven A. Pergam, Grace Mishkin, Melissa Bowman +8 more

Larissa A. Korde

Indexed papers

Top data-sharing exemplar

Papers